J&J Starts The Year With A Bang: 22 Early-Stage Deals
This article was originally published in Scrip
Johnson & Johnson revealed 22 research collaborations and partnerships on Jan. 7, running the gambit across the company's diversified business and highlighting its emphasis on tapping external sources for innovation.
You may also be interested in...
Scrip's second full day of meetings and events during the annual BIO International Convention delivered diverse insights about including patients in drug development, sharing risk with CROs, microbiome-targeting therapies, and the benefits of incubating early-stage technology.
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.